Drugs / BMS-986365
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07242781 | Dec 2025 → Apr 2026 | — | Celgene Corporation | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT06433505 | May 2024 → Feb 2025 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT06417229 | May 2024 → Feb 2025 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06764485 | Mar 2025 → Sep 2027 expected | prostate carcinoma | Celgene Corporation | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-01-17 | Bristol-Myers Squibb | Results Bristol Myers Squibb Data at ASCO GU 2024 Showcase Transformative Research in the Treatment of Genitourinary Cancers bms.com ↗
First presentation of clinical outcomes from the company’s targeted protein degradation platform in solid tumors with Phase 1 data from BMS-986365 (CC-94676), an oral drug selectively targeting AR. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-01-17 | Bristol-Myers Squibb | Bristol Myers Squibb Data at ASCO GU 2024 Showcase Transformative Research in the Treatment of Genitourinary Cancers bms.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-986365 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06417229 ↗ |
| Known as | [14C] BMS-986365 | “Drug: [14C] BMS-986365” NCT06433505 ↗ |
| Action | Inhibit | “dual mechanism of AR degradation and antagonism” PMID 40455815 ↗ Jun 2025 |
| Modality | Other / unclassified | “BMS-986365 is a heterobifunctional, orally bioavailable ligand-directed degrader” PMID 40455815 ↗ Jun 2025 |
| Route | Oral | “The rechARge study is evaluating a new oral drug called BMS-986365” PMID 40455815 ↗ Jun 2025 |
| Target | AR | “targets the AR through a first-in-class dual mechanism” PMID 40455815 ↗ Jun 2025 |